A Roadmap for Proving Clinical Efficacy and Economic Value: Interview with Mainstay Medical CEO Jason Hannon

In this episode of Medsider Radio, we sat down with Jason Hannon, President and CEO of Mainstay Medical, where he and his team are commercializing ReActiv8, an implantable neurostimulation system for intractable mechanical chronic low back pain. Jason holds a J.D. from Stanford University Law School and a B.A. from the University of California, Berkeley. After 12 years at NuVasive, where as COO, he led the company to incredible revenue milestones, he transitioned to his current role at Mainstay. In this interview, Jason shares his experiences on iterative product development, considerations for clinical trial design, the importance of patient education, and why reimbursement is paramount.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Jason Hannon.